This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Tepkinly (epcoritamab)
General Description:
Tepkinly (epcoritamab) is a prescription medicine indicated for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior lines of treatment. As a bispecific antibody therapy, it helps the immune system identify and attack cancerous B-cells, providing an important treatment option for eligible patients.
Getting Tepkinly (epcoritamab) in India:
Tepkinly (epcoritamab) is approved in the United States, Japan (marketed as Epkinly), and the European Union. While it is not commercially available in India, eligible patients may be able to access the medicine through the Named Patient Program (NPP) with a valid prescription.
MitoGENE supports patients and healthcare providers with documentation, import coordination, and delivery in accordance with Indian regulatory requirements.
Disease Indications: Lymphoma
Usage: Subcutaneous
Medicine Approved By: European Medical Agency (EMA)
Available Dosage Form & Package:
• single-dose vial x 4 mg/0.8 mL
• single-dose vial x 48 mg
Shipping:
Cold chain shipping is required to maintain the stability and effectiveness of Tepkinly during transportation. Specialized temperature-controlled packaging and medical courier services are used to ensure safe delivery.
How to Access Tepkinly (epcoritamab) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Tepkinly (epcoritamab) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in obtaining it legally through the Named Patient Program (NPP).
Here’s how the process works:
